Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 3/20 | 0.31 |
| ▸ | GPR6 | P46095 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632571 | 0.90 | GRM5 (0.37) | GRM5KDM4EALDH1A1P4HBAR | |
| SCHEMBL16632725 | 0.88 | GRM5 (0.34) | GRM5ARAXL | |
| SCHEMBL16632447 | 0.87 | AR (0.39) | GRM5AR | |
| SCHEMBL16632347 | 0.84 | GRM5 (0.41) | GRM5KDM4EALDH1A1AR | |
| SCHEMBL16632728 | 0.84 | AR (0.46) | GRM5KDM4EALDH1A1AR | |
| SCHEMBL16632575 | 0.81 | AR (0.39) | GRM5ARGPR6SCN9A | |
| SCHEMBL16632433 | 0.79 | TTR (0.44) | AR | |
| SCHEMBL16632694 | 0.79 | GRM5 (0.37) | GRM5P4HBARGPR6SCN9A | |
| SCHEMBL16632561 | 0.78 | AR (0.41) | GRM5KDM4EALDH1A1AR | |
| SCHEMBL16632488 | 0.76 | AR (0.48) | GRM5KDM4EALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | GRM5 2115/4885KDM4E 2839/4885ALDH1A1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.